Med­Co builds its case for star cho­les­terol RNAi ther­a­py with two new pos­i­tive piv­otal stud­ies

Weeks af­ter un­veil­ing late-stage da­ta that gave its cho­les­terol fight­er a clean safe­ty pro­file, The Med­i­cines Com­pa­ny is back with two more Phase III datasets sup­port­ive of the ex­per­i­men­tal ther­a­py’s ben­e­fit-risk record — as the New Jer­sey drug de­vel­op­er works on carv­ing it­self a slice of the lu­cra­tive car­dio­vas­cu­lar mar­ket.

On Wednes­day, the com­pa­ny said its drug, in­clisir­an, cleared the pri­ma­ry and sec­ondary goals in the 1,561-pa­tient ORI­ON-10 study, in­volv­ing pa­tients with ath­er­o­scle­rot­ic car­dio­vas­cu­lar dis­ease who were al­ready on LDL-cho­les­terol (LDL-C) low­er­ing ther­a­pies such as statins or eze­tim­ibe.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER